The short version of ghrelin receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-30 and is reviewed periodically as new material appears.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Value for the free base |
| Molar mass | 711.9 g/mol | Calculated from the formula |
| Appearance | White to off-white powder | Typical lyophilized form |
| Mechanism class | Ghrelin receptor agonist | Also described as a secretagogue |
| Half-life | About 2 hours | Reported for human circulation |
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
The Unionists, by and large, regarded Germany as a dangerous rival, and rejoiced at the chance to destroy her. They meant to fight a hard-headed war by ruthless methods; they condemned Liberal 'softness' before the war and now. The Liberals insisted on remaining high-minded. Many of them had come to support the war only when the Germans invaded Belgium. [...] Entering the war for idealistic motives, the Liberals wished to fight it by noble means and found it harder to abandon their principles than to endure defeat in the field. The 1915 coalition fell apart at the end of 1916, when the Conservatives withdrew their support from Asquith and gave it instead to Lloyd George, who became prime minister at the head of a new coalition largely made up of Conservatives. Asquith and his followers moved to the opposition benches in Parliament and the Liberal Party was deeply split once again.
According to the operators, the MIC tank pressure gauge had been malfunctioning for roughly a week. Other tanks were used, rather than repairing the gauge. The build-up in temperature and pressure is believed to have affected the magnitude of the gas release. UCC admitted in their own investigation report that most of the safety systems were not functioning on the night of 3 December 1984. The design of the MIC plant, following government guidelines, was "Indianized" by UCIL engineers to maximise the use of indigenous materials and products. Mumbai-based Humphreys and Glasgow Consultants Pvt. Ltd., were the main consultants, Larsen & Toubro fabricated the MIC storage tanks, and Taylor of India Ltd. provided the instrumentation. In 1998, during civil action suits in India, it emerged that the plant was not prepared for problems. No action plans had been established to cope with accidents of this magnitude. This included not informing local authorities of the quantities or dangers of chemicals used and manufactured at Bhopal.
==== Cotranslational folding ==== The ribosome is known to actively participate in the protein folding. The structures obtained in this way are usually identical to the ones obtained during protein chemical refolding; however, the pathways leading to the final product may be different. In some cases, the ribosome is crucial in obtaining the functional protein form. For example, one of the possible mechanisms of folding of the deeply knotted proteins relies on the ribosome pushing the chain through the attached loop.
==== Type II antithrombin deficiency ==== Type II antithrombin deficiency is characterized by normal antithrombin levels but reduced antithrombin activity in the blood of affected individuals. It was originally proposed that type II deficiency be further divided into three subgroups (IIa, IIb, and IIc) depending on which antithrombin functional activity is reduced or retained.
== Technique == The technique initially incubates a small amount of abnormal prion with an excess of normal protein, so that some conversion takes place. The growing chain of misfolded protein is then blasted with ultrasound, breaking it down into smaller chains and so rapidly increasing the amount of abnormal protein available to cause conversions. By repeating the cycle, the mass of normal protein is rapidly changed into the prion being tested for.
Sources: en.wikipedia.org
== Risk management and regulations == Aflatoxin B1 exposure is best managed by measures aimed at preventing contamination of crops in the field, post-harvest handling, and storage, or via measures aimed at detecting and decontaminating contaminated commodities or materials used in animal feed. For instance, biological decontamination involving the use of a single bacterial species, Flavobacterium aurantiacum has been used to remove aflatoxin B1 from peanuts and corn. Several countries around the world have rules and regulations governing aflatoxin B1 in foods and these include the maximum permitted, or recommended levels of aflatoxin B1 for certain foods.
== Bibliography == Boyd Orr, John (1905). Scotch Church Crisis: The Full Story of the Modern Phase of the Presbyterian Struggle. Glasgow: John M'Neilage. —————— (1929). Minerals in Pastures and Their Relation to Animal Nutrition. London: Lewis. —————— (1934). The National Food Supply and Its Influence on Public Health. London: King. —————— (1936). Food, Health and Income. London: Macmillan. —————— (1937). Nutritional Science and State Planning.in (Orr) —————— (1940). Nutrition in war. Fabian Tract 251. London: Fabian Society. —————— (1942). Fighting for What?. London: Macmillan. —————— (1943). Food and the People. London: Pilot Press. —————— (1945). Welfare and Peace. London: National Peace Council. —————— (1946). A Charter for Health. London: Allen & Unwin. —————— (1948). Food: The Foundation of World Unity. London: National Peace Council. —————— (1950). International Liaison Committee of Organisations for Peace: A New Strategy of Peace. London: National Peace Council. —————— (1957). Feast and famine: The wonderful world of food. London: Rathbone Books. —————— (1958). The Wonderful World of Food: The Substance of Life. Garden City, NY: Garden City Books. —————— (1966). As I recall: the 1880s to the 1960s. with an introduction by Ritchie Calder. London: MacGibbon & Kee. with other authors Boyd Orr, John; Lubbock, David (1940). Feeding the people in war time. London: Macmillan – via Internet Archive. Boyd Orr, John; Lubbock, David (1964) [First published 1953]. The White Man's Dilemma: Food and the Future (2nd ed.). London: Allen & Unwin. Boyd Orr, John (1968).
==== Declined ==== Grant Moody, Bexar County commissioner from the 3rd precinct Kyle Sinclair, former vice chair of the Bexar County Republican Party, candidate for the 28th district in 2024 and nominee for the 20th district in 2022 (ran in the 21st district)
=== Sphincters === The esophagus is surrounded at the top and bottom by two muscular rings, known respectively as the upper esophageal sphincter and the lower esophageal sphincter. These sphincters act to close the esophagus when food is not being swallowed. The upper esophageal sphincter is an anatomical sphincter, which is formed by the lower portion of the inferior pharyngeal constrictor, also known as the cricopharyngeal sphincter due to its relation with cricoid cartilage of the larynx anteriorly. However, the lower esophageal sphincter is not an anatomical but rather a functional sphincter, meaning that it acts as a sphincter but does not have a distinct thickening like other sphincters. The upper esophageal sphincter surrounds the upper part of the esophagus. It consists of skeletal muscle but is not under voluntary control. Opening of the upper esophageal sphincter is triggered by the swallowing reflex. The primary muscle of the upper esophageal sphincter is the cricopharyngeal part of the inferior pharyngeal constrictor. The lower esophageal sphincter, or gastroesophageal sphincter, surrounds the lower part of the esophagus at the gastroesophageal junction between the esophagus and the stomach. It is also called the cardiac sphincter or cardioesophageal sphincter, named from the adjacent part of the stomach, the cardia. Dysfunction of the gastroesophageal sphincter causes gastroesophageal reflux, which causes heartburn, and, if it happens often enough, can lead to gastroesophageal reflux disease, with damage of the esophageal mucosa.
Electroconvulsive therapy can differ in its application in three ways: electrode placement, frequency of treatments, and the electrical waveform of the stimulus. These three forms of application have significant differences in both adverse side effects and symptom remission. After treatment, drug therapy is usually continued, and some patients receive maintenance ECT. ECT appears to work in the short term via an anticonvulsant effect mostly in the frontal lobes, and longer term via neurotrophic effects primarily in the medial temporal lobe.
Sources: en.wikipedia.org
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.
It binds the ghrelin receptor, known as the growth hormone secretagogue receptor type 1a. Activation of that receptor triggers signaling that leads to growth hormone release. Selectivity for growth hormone over cortisol and prolactin is the property most often cited for this compound.
Published estimates place the circulating half-life at roughly two hours in humans. Clearance involves peptidase activity and renal handling. Because the peptide is short-lived, release patterns after administration are usually described as pulsatile rather than sustained.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.